Mutual of America Capital Management LLC Sells 75,782 Shares of Supernus Pharmaceuticals, Inc. - MarketBeat
SUPN Stock | USD 35.82 0.30 0.83% |
About 54% of Supernus Pharmaceuticals' investor base is interested to short. The analysis of overall sentiment of trading Supernus Pharmaceuticals stock suggests that many investors are impartial at this time. Supernus Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Supernus Pharmaceuticals. Many technical investors use Supernus Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Supernus |
Mutual of America Capital Management LLC Sells 75,782 Shares of Supernus Pharmaceuticals, Inc. MarketBeat
Read at news.google.com
Supernus Pharmaceuticals Current Investor Sentiment
Panic Vs Confidence
46
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Supernus Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Supernus Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Supernus Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Supernus Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Supernus Pharmaceuticals Historical Investor Sentiment
Investor biases related to Supernus Pharmaceuticals' public news can be used to forecast risks associated with an investment in Supernus. The trend in average sentiment can be used to explain how an investor holding Supernus can time the market purely based on public headlines and social activities around Supernus Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Supernus Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Supernus Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Supernus Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Supernus Pharmaceuticals.
Supernus Pharmaceuticals Fundamental Analysis
We analyze Supernus Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Supernus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Supernus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Supernus Pharmaceuticals is currently under evaluation in target price category among its peers.
Supernus Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Supernus Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Supernus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Supernus Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Supernus Pharmaceuticals Related Equities
PCRX | Pacira BioSciences, | 2.06 | ||||
PBH | Prestige Brand | 1.78 | ||||
PAHC | Phibro Animal | 1.58 | ||||
ANIP | ANI Pharmaceuticals | 1.38 | ||||
COLL | Collegium Pharmaceutical | 1.37 | ||||
EVO | Evotec SE | 0.94 | ||||
RGC | Regencell Bioscience | 0.88 | ||||
RDY | Dr Reddys | 2.17 |
Check out Supernus Pharmaceuticals Hype Analysis, Supernus Pharmaceuticals Correlation and Supernus Pharmaceuticals Performance. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.07 | Revenue Per Share 11.877 | Quarterly Revenue Growth 0.142 | Return On Assets 0.0289 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.